Display options
Cite
Lange C, Mäurer A, Suppa P, et al. Brain FDG PET for Short- to Medium-Term Prediction of Further Cognitive Decline and Need for Assisted Living in Acutely Hospitalized Geriatric Patients With Newly Detected Clinically Uncertain Cognitive Impairment. Clin Nucl Med. 2022;47(2):123-129doi: 10.1097/RLU.0000000000003981.
Lange, C., Mäurer, A., Suppa, P., Apostolova, I., Steffen, I. G., Grothe, M. J., & Buchert, R. (2022). Brain FDG PET for Short- to Medium-Term Prediction of Further Cognitive Decline and Need for Assisted Living in Acutely Hospitalized Geriatric Patients With Newly Detected Clinically Uncertain Cognitive Impairment. Clinical nuclear medicine, 47(2), 123-129. https://doi.org/10.1097/RLU.0000000000003981
Lange, Catharina, et al. "Brain FDG PET for Short- to Medium-Term Prediction of Further Cognitive Decline and Need for Assisted Living in Acutely Hospitalized Geriatric Patients With Newly Detected Clinically Uncertain Cognitive Impairment." Clinical nuclear medicine vol. 47,2 (2022): 123-129. doi: https://doi.org/10.1097/RLU.0000000000003981
Lange C, Mäurer A, Suppa P, Apostolova I, Steffen IG, Grothe MJ, Buchert R. Brain FDG PET for Short- to Medium-Term Prediction of Further Cognitive Decline and Need for Assisted Living in Acutely Hospitalized Geriatric Patients With Newly Detected Clinically Uncertain Cognitive Impairment. Clin Nucl Med. 2022 Feb 01;47(2):123-129. doi: 10.1097/RLU.0000000000003981. PMID: 35006106.
Copy Download .nbib Format: NLM
Share it on

Clin Nucl Med. 2022 Feb 01;47(2):123-129. doi: 10.1097/RLU.0000000000003981.

Brain FDG PET for Short- to Medium-Term Prediction of Further Cognitive Decline and Need for Assisted Living in Acutely Hospitalized Geriatric Patients With Newly Detected Clinically Uncertain Cognitive Impairment.

Clinical nuclear medicine

Catharina Lange, Anja Mäurer, Per Suppa, Ivayla Apostolova, Ingo G Steffen, Michel J Grothe, Ralph Buchert

Affiliations

  1. From the Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin.
  2. Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg.
  3. Department of Radiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  4. Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.

PMID: 35006106 DOI: 10.1097/RLU.0000000000003981

Abstract

PURPOSE: The aim of this study was to evaluate brain FDG PET for short- to medium-term prediction of cognitive decline, need for assisted living, and survival in acutely hospitalized geriatric patients with newly detected clinically uncertain cognitive impairment (CUCI).

MATERIALS AND METHODS: The study included 96 patients (62 females, 81.4 ± 5.4 years) hospitalized due to (sub)acute admission indications with newly detected CUCI (German Clinical Trials Register DRKS00005041). FDG PET was categorized as "neurodegenerative" (DEG+) or "nonneurodegenerative" (DEG-) based on visual inspection by 2 independent readers. In addition, each individual PET was tested voxel-wise against healthy controls (P < 0.001 uncorrected). The resulting total hypometabolic volume (THV) served as reader-independent measure of the spatial extent of neuronal dysfunction/degeneration. FDG PET findings at baseline were tested for association with the change in living situation and change in vital status 12 to 24 months after PET. The association with the annual change of the CDR-SB (Clinical Dementia Rating Sum of Boxes) after PET was tested in a subsample of 72 patients.

RESULTS: The mean time between PET and follow-up did not differ between DEG+ and DEG- patients (1.37 ± 0.27 vs 1.41 ± 0.27 years, P = 0.539). Annual change of CDR-SB was higher in DEG+ compared with DEG- patients (2.78 ± 2.44 vs 0.99 ± 1.81, P = 0.001), and it was positively correlated with THV (age-corrected Spearman ρ = 0.392, P = 0.001). DEG+ patients moved from at home to assisted living significantly earlier than DEG- patients (P = 0.050). Survival was not associated with DEG status or with THV.

CONCLUSIONS: In acutely hospitalized geriatric patients with newly detected CUCI, the brain FDG PET can contribute to the prediction of further cognitive/functional decline and the need for assisted living within 1 to 2 years.

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Conflict of interest statement

Conflicts of interest and sources of funding: This work was supported by the Regional Development Fund of the European Union (10153407, 10153971, 10153458, 10153460, 10153461, 10153462, 10153463) and

References

  1. Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954–963. - PubMed
  2. Harper L, Barkhof F, Scheltens P, et al. An algorithmic approach to structural imaging in dementia. J Neurol Neurosurg Psychiatry. 2014;85:692–698. - PubMed
  3. Koikkalainen J, Rhodius-Meester H, Tolonen A, et al. Differential diagnosis of neurodegenerative diseases using structural MRI data. Neuroimage Clin. 2016;11:435–449. - PubMed
  4. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001;286:2120–2127. - PubMed
  5. Bohnen NI, Djang DS, Herholz K, et al. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J Nucl Med. 2012;53:59–71. - PubMed
  6. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–629. - PubMed
  7. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486–510. - PubMed
  8. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104–1113. - PubMed
  9. Giovacchini G, Squitieri F, Esmaeilzadeh M, et al. PET translates neurophysiology into images: a review to stimulate a network between neuroimaging and basic research. J Cell Physiol. 2011;226:948–961. - PubMed
  10. Silverman DH, Truong CT, Kim SK, et al. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Mol Genet Metab. 2003;80:350–355. - PubMed
  11. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74:201–209. - PubMed
  12. Ritter K, Lange C, Weygandt M, et al. Combination of structural MRI and FDG-PET of the brain improves diagnostic accuracy in newly manifested cognitive impairment in geriatric inpatients. J Alzheimers Dis. 2016;54:1319–1331. - PubMed
  13. Brindle N, Holmes J. Capacity and coercion: dilemmas in the discharge of older people with dementia from general hospital settings. Age Ageing. 2005;34:16–20. - PubMed
  14. Apostolova I, Lange C, Roberts A, et al. Challenges in screening and recruitment for a neuroimaging study in cognitively impaired geriatric inpatients. J Alzheimers Dis. 2017;56:197–204. - PubMed
  15. Mathies F, Lange C, Maurer A, et al. Brain FDG PET for the etiological diagnosis of clinically uncertain cognitive impairment during delirium in remission. J Alzheimers Dis. 2020;77:1609–1622. - PubMed
  16. Varrone A, Asenbaum S, Vander Borght T, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103–2110. - PubMed
  17. Lange C, Suppa P, Frings L, et al. Optimization of statistical single subject analysis of brain FDG PET for the prognosis of mild cognitive impairment-to-Alzheimer's disease conversion. J Alzheimers Dis. 2016;49:945–959. - PubMed
  18. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198. - PubMed
  19. Williams MM, Storandt M, Roe CM, et al. Progression of Alzheimer's disease as measured by Clinical Dementia Rating Sum of Boxes scores. Alzheimers Dement. 2013;9:S39–S44. - PubMed
  20. Cedarbaum JM, Jaros M, Hernandez C, et al. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials. Alzheimers Dement. 2013;9:S45–S55. - PubMed
  21. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61–65. - PubMed
  22. Jackson TA, MacLullich AM, Gladman JR, et al. Diagnostic test accuracy of informant-based tools to diagnose dementia in older hospital patients with delirium: a prospective cohort study. Age Ageing. 2016;45:505–511. - PubMed
  23. Jorm AF. The informant questionnaire on cognitive decline in the elderly (IQCODE): a review. Int Psychogeriatr. 2004;16:275–293. - PubMed
  24. Harwood DM, Hope T, Jacoby R. Cognitive impairment in medical inpatients. I: screening for dementia—is history better than mental state?Age Ageing. 1997;26:31–35. - PubMed
  25. Burdette JH, Minoshima S, Vander Borght T, et al. Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections. Radiology. 1996;198:837–843. - PubMed
  26. Arbizu J, Prieto E, Martinez-Lage P, et al. Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia. Eur J Nucl Med Mol Imaging. 2013;40:1394–1405. - PubMed
  27. Herholz K, Westwood S, Haense C, et al. Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. J Nucl Med. 2011;52:1218–1226. - PubMed
  28. Ritter K, Schumacher J, Weygandt M, et al. Multimodal prediction of conversion to Alzheimer's disease based on incomplete biomarkers. Alzheimers Dement (Amst). 2015;1:206–215. - PubMed
  29. Morbelli S, Brugnolo A, Bossert I, et al. Visual versus semi-quantitative analysis of 18F-FDG-PET in amnestic MCI: an European Alzheimer's Disease Consortium (EADC) project. J Alzheimers Dis. 2015;44:815–826. - PubMed
  30. Caminiti SP, Ballarini T, Sala A, et al. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. Neuroimage Clin. 2018;18:167–177. - PubMed
  31. Mathews SB, Arnold SE, Epperson CN. Hospitalization and cognitive decline: can the nature of the relationship be deciphered?Am J Geriatr Psychiatry. 2014;22:465–480. - PubMed

Publication Types